#Israel #Inspira Technologies #INSPIRA ART100 #HYLA Blood Sensor #Ra'anana

Inspira Technologies Reports Full Year 2024 Financial Results and Business Updates

In an exciting display of progress, Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) announced their financial results for the full year ending December 31, 2024, alongside major business developments. This Israeli company is recognized for its pioneering work in innovative life-support and diagnostic technologies.

Technological Advancements Mark 2024

The CEO of Inspira, Dagi Ben-Noon, expressed that 2024 was transformative for the company, highlighting notable technological strides and essential regulatory achievements. A landmark event was obtaining 510(k) clearance from the Food and Drug Administration (FDA) for the company’s flagship INSPIRA ART100 system. This approval paves the way for deployment in prestigious hospitals across the U.S.

Looking ahead, the company aims to enhance its core technologies further exemplified by the HYLA blood monitoring sensor—a groundbreaking device expected to undergo FDA submission in the latter half of 2025. Impressively, the INSPIRA ART100 system has already been implemented at Westchester Memorial Center, New York, for thorough evaluations by medical experts during clinical procedures.

Recent Highlights and Developments

In January 2025, Inspira began distributing the FDA-approved INSPIRA ART100 systems through a partnership with Glo-Med Networks Inc., extending to hospitals along the East Coast. This deployment, targeting a reputable cardiothoracic surgery division at a top-ranking New York hospital, ensures a smooth integration of this unique technology into clinical practices.

Further advancements include the introduction of a modular configuration for their VORTX blood oxygenation technology which can significantly alter critical care methodologies by minimizing the detrimental effects on blood components.

In March 2025, promising results emerged from clinical studies of the AI-powered HYLA blood sensor, which attained an impressive 96% accuracy compared to standard blood test analyzers. Notably, the device demonstrated a 92.3% accuracy rate for a novel indicator of oxygen deficiencies during real-time monitoring in patients undergoing open-heart surgeries.

Strategic Partnerships and Enhanced Systems

To bolster production capabilities, Inspira forged a partnership with Zriha Medical Ltd., launching a dedicated production line for a crucial flow mechanism component meant for their innovative respiratory support system. This collaboration is expected to increase their ability to scale solutions effectively.

Additionally, in January, enhancements to the INSPIRA ART100 system were made to facilitate better support features, aiming at assisting medical teams in their tasks, streamlining operational efficiency, and reducing labor overhead.

Infection control technology also gained momentum, with positive results reported from collaboration with Ennocure MedTech Ltd., showcasing a remarkable 95% reduction in bacterial presence within four hours through pioneering bio-electronic patch technologies.

Financial Overview for 2024

The financial landscape of Inspira Technologies has displayed improvements, especially amidst measured operating expenses and strategic RD investments. Total operating expenses decreased slightly to $11.27 million from $12.13 million year-on-year, while RD investments also saw a reduction from $7.32 million to $6.32 million due to various operational optimizations.

General and Administrative (GA) expenses edged up to about $4.19 million, attributed mainly to increased professional fees. Sales and marketing expenses showed a marginal rise, which can be linked to amplified salary costs.

At the core of their financial results, Inspira reported a net loss amounting to $11.05 million, only a slight decline from the previous year's $11.29 million. Their cash position experienced a dip, resting at approximately $5.78 million, which, despite the decrease, continues to provide a resilient foundation for ongoing product development and regulatory preparations.

As financial reporting is crucial for the company, Inspira Technologies aims to leverage these results for subsequent strategic planning while remaining optimistic about future technological innovations.

Conclusion

Inspira Technologies stands at an exciting juncture as they navigate the dynamic landscape of medical technology. With enhancements in their product line, impending FDA submissions, and consistent financial management, the company is well-positioned to make impactful advancements in life-support systems and critical care technologies that can dramatically improve patient outcomes.